Clinical Trial Update: A Study of Oral Upadacitinib (RINVOQ) Tablets to Assess Adverse Events and Change in Disease Symptoms in Korean Participants With Moderate to Severe Active Rheumatoid Arthritis, Atopic Dermatitis, Ankylosing Spondylitis or Psoriatic Arthritis

View source ↗

Summary

A completed clinical trial evaluating adverse events and changes in disease symptoms in Korean participants with rheumatoid arthritis, atopic dermatitis, ankylo…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Ankylosing Spondylitis
• Atopic Dermatitis
• Psoriatic Arthritis
• Rheumatoid Arthritis

Drugs mentioned

• RINVOQ (Upadacitinib)

Snippet

Sponsor: AbbVie | Conditions: Rheumatoid Arthritis (RA), Atopic Dermatitis (AD) | Status: COMPLETED